The Efficacy and Safety Profile of Ixazomib-Based Regimens in Patients with Relapsed/Refractory Multiple Myeloma in Routine Clinical Practice: Real World Data from a Multi-Center Study in China
Year: 2019
Type: conference-abstract
Source: Blood
Institutions: Fudan University, Zhongshan Hospital, Beijing Jishuitan Hospital, Sun Yat-sen University Cancer Center, Second Affiliated Hospital of Soochow University, Nanjing Drum Tower Hospital, Nanjing University, First Affiliated Hospital of Soochow University, First Affiliated Hospital of Xiamen University, XinHua Hospital, Wuxi People's Hospital, Affiliated Hospital of Hebei University, China Medical University, First Affiliated Hospital of GuangXi Medical University, Zhujiang Hospital, Southern Medical University
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Keywords: ixazomib, relapsed/refractory multiple myeloma, oral proteasome inhibitor, lenalidomide, dexamethasone, real-world effectiveness, treatment safety, adverse events, newly diagnosed multiple myeloma, maintenance therapy, Chinese patients, routine clinical practice, progression-free survival, response rate
Open Access status: closed
OpenAlex ID: W2983138238
